医药生物行业点评：二季度建议逐步增加医药板块配置比例

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the benchmark index in the next 6-12 months [20]. Core Insights - The report suggests gradually increasing the allocation to the pharmaceutical sector in the second quarter, as the overall valuation remains low at an average of 24.43 times as of March 27, 2024 [2][4]. - Concerns among investors are expected to ease as the impact of "pharmaceutical anti-corruption" factors diminishes, leading to a potential recovery in performance throughout 2024 [2][4]. - The government's clear support for innovation in the pharmaceutical industry is anticipated to gradually materialize across the entire industry chain [4][15]. Summary by Sections Industry Performance - The pharmaceutical sector has shown relatively weak performance recently, with the SW Pharmaceutical Index declining by 2.96% from March 1 to March 27, 2024, underperforming the CSI 300 Index by 2.58 percentage points [3][6]. - Among sub-sectors, the medical services sector saw a decline of 7.99%, while the traditional Chinese medicine and chemical pharmaceutical sectors managed slight gains of 0.41% and 0.53%, respectively [8][10]. Valuation and Growth Potential - The pharmaceutical sector's valuation is at historical lows, with a TTM P/E ratio of 24.43 as of March 27, 2024 [11][12]. - The report anticipates a gradual acceleration in earnings growth starting in the second quarter, as the negative impacts from high performance bases in the first quarter of 2023 and "pharmaceutical anti-corruption" factors begin to fade [12][13]. Policy Support and Long-term Outlook - The report highlights a shift in policy towards stronger support for pharmaceutical innovation, with the 2024 government work report emphasizing the importance of the biopharmaceutical industry as a new productive force [15][16]. - Long-term growth potential in the innovative drug sector is supported by China's large population, abundant clinical research resources, and a pool of skilled talent in the life sciences [16]. Investment Recommendations - The report recommends focusing on investment opportunities in innovative drugs and devices, particularly companies expected to see significant sales growth in 2024, such as Heng Rui Medicine and Innovent Biologics [5].